Cancer is caused by defective genes, but what also shapes the behavior of cancer cells is how the instructions in genes are trimmed and rearranged before they are converted into the proteins that keep cells alive.
Research published in nature communications uncover a new way to directly measure the editing process known as splicing. This is the first time scientists have a clear picture of how tumors systematically rewire their genetic instructions to help them grow and survive, potentially pointing to new ways to control the disease.
As a proof of concept, the researchers used the method on solid tumor biopsies. They discovered about 120 potential new therapeutic targets, molecules that could one day be dialed up or dialed down to restore balance to the cell’s editing machinery.
Instead of counting parts, our approach was to understand behavior, and this opened new ways to navigate the chaotic biology of tumors. Although it’s still early days, we now have a clearer map of where to look to find new ways to target the disease. ”
Dr. Miquel Anglada-Girotto, Research Lead Author and Postdoctoral Researcher, Center for Genome Regulation
Measure edits on behalf of editors
Inside every cell, genetic instructions are first copied into temporary messages. Before these messages are used, the cell cuts out some segments and stitches the rest together. This editing step allows a single gene to create different messages that produce different proteins, a necessary function for complex life.
Almost all cancers hijack the splicing of cells, changing the way they cut and paste messages. Tumors do this to produce protein variants that help them grow faster, hide from the immune system, and resist treatment.
To understand this process, scientists typically measure the molecules that perform the editing, also known as splicing factors. However, these cellular editors can be controlled in many covert ways, and their activity remains seemingly unchanged even while the protein itself is destroyed, chemically modified, or moved to another part of the cell. The result is often a confusing situation that hinders progress in the search for new ways to control the disease.
A team from the Center for Genome Regulation in Barcelona and Columbia University addressed this problem by reversing the logic and measuring the edits themselves rather than the editor.
The researchers applied an existing technique called VIPER to measure which segments of a gene’s message are retained and which are deleted. These patterns act like fingerprints on genetic messages, revealing which editing forces were actually at work, regardless of how editors were regulated.
This technique can be used on widely available RNA-seq data. This means the technique can be applied to thousands of existing samples without conducting new experiments.
Two hidden cancer programs
The researchers applied VIPER to approximately 10,000 tumor biopsies from 14 different cancer types in The Cancer Genome Atlas, a publicly available database. Each biopsy is paired with a matched healthy tissue sample for comparison.
They discovered two widespread cell editing programs that recur across all types of cancer. One program acted like an accelerator, becoming more active against tumors and working as patient outcomes worsened. The other acted like a brake, losing strength in cancer and aligning it with better survival rates.
The findings suggest that despite their diversity, cancers share common cell-editing strategies that have been hidden by studies that only look at genes.
When researchers looked for biological features that could help tip a cell’s editing balance toward cancer, they found about 100 candidates. Among the most prominent was a gene called FUS, which is well known for its role in neurological symptoms. Although not widely studied in cancer research, its strong predictive signal suggests that it deserves more attention.
Its impact extends beyond cancer. Because the technology focuses on the consequences of gene editing rather than specific causes, it could be applied to many diseases that alter the way cells assemble instructions.
“We started with cancer because the data were available, but this approach could be effective in any disease that changes the way cells edit messages, such as neurological or immune diseases,” concludes Dr. Anglada-Girotto.
sauce:
genome control center
Reference magazines:
Anglada Gilot, M. Others. (2026). Exon inclusion signatures allow accurate estimation of splicing factor activity. nature communications. DOI: 10.1038/s41467-026-69642-3. https://www.nature.com/articles/s41467-026-69642-3.
